SLBT SLBT
Company Profile ↓Company Overview
SLBT (SLBT) is a publicly traded company listed on with a market capitalization of $1.57B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 58.1% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.09.
Recent Developments
- Dec 2025 Revenue of $2.20M (-34.7% YoY); net profit $-3.82M.
- Trailing 12 Months Year-on-year growth — revenue -34.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 58.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 58.11% |
| 1 Year: | -34.68% |
Stock Price Performance
| 1 Year: | -72.71% |
| 6 Months: | -73.51% |
| 3 Months: | -66.86% |
| 1 Month: | -37.22% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.96 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 58.1% over 5 years.
CONS
- Trading 78.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 878.97K | 3.36M | 2.20M |
| Cost of Revenue | 140.96K | 1.43M | 1.42M |
| Gross Profit | 738.01K | 1.93M | 775.06K |
| Operating Expenses | 641.18K | 3.13M | 4.61M |
| Operating Income | 96.83K | -1.20M | -3.84M |
| EBITDA | 134.02K | -1.15M | -3.74M |
| Interest Expense | - | - | - |
| Pretax Income | 532.87K | -1.13M | -3.82M |
| Tax Provision | 133.84K | 57.63K | -4 |
| Net Income | 399.04K | -1.19M | -3.82M |
| Diluted EPS | 0.00 | -0.00 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 4.24M | 5.93M | 2.82M |
| Current Assets | 3.49M | 5.86M | 1.43M |
| Cash & Equivalents | 276.85K | 3.68M | 1.26M |
| Inventory | 1.48M | 1.36M | 0 |
| Receivables | 26.88K | 0 | - |
| Total Liabilities | 668.07K | 204.90K | 533.28K |
| Current Liabilities | 183.03K | 69.20K | 468.54K |
| Long Term Debt | - | - | - |
| Total Debt | 550.06K | 0 | 213.41K |
| Total Equity | 3.57M | 5.73M | 2.28M |
| Shares Outstanding | 560.76M | 560.76M | 560.76M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -2.45M | 280.16K | -1.91M |
| Investing Cash Flow | -182.98K | 123.28K | -319.69K |
| Financing Cash Flow | 2.86M | 3.07M | -879.14K |
| Capital Expenditure | -182.98K | -7.97K | -319.69K |
| Free Cash Flow | -2.64M | 272.19K | -2.23M |
| Net Change in Cash | 223.65K | 3.47M | -3.11M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 84.0% | 57.5% | 35.3% |
| Operating Margin % | 11.0% | -35.6% | -174.6% |
| Net Margin % | 45.4% | -35.4% | -173.8% |
| ROE % | 11.2% | -20.8% | -167.2% |
| ROCE % | 2.4% | -20.4% | -163.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SLBT
SL Science Holding Limited (SLBT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiTkFVX3lxTE1DSGdHNjNTMUVTa0M1MmUtRWJWZXNoaUhELS1SSHg4WEFqTUlyUm85Z01QV0xXc1EyMGEwdmdITDNpdkI3UWVnV3NucHo2dw?oc=5" target="_blank">SL Science Holding Limited (SLBT) Stock Price | Live Quotes &…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBka2Z6R2FhdEh0bEpVREVtaHBmeGp2eVBla3RpTE5EeU1LT0hGQmNtMTNnbzU2VzJJaDJLVUpRaklqMS1XTW1ZWUdYWWNadWFu?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Number of shareholders of SL Science Holding Limited – NASDAQ:SLBT - TradingView
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNWEdNbGV0aE43SEs5Nm1wYzNqLUhjMG5RMTd1SVYyN0JFMEZtbFBYUzhSYTgxQ0lPbE5hUk1nWmN0Smxrcjg1RURzSElvNmNpWDh2dGhnQjUwNFpfR3ZDb3NrU0RkSVRsT3RGenhkRkh5WlYwWVdtMjNjUjlvdWlGclNTc0NCX0Q0ZFNaYn…
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQem91VndnYkFWUUR4WWNkRTZlTTl2bkJVTUFuMndKUVdDbEk5ZUc1NHR1alhlTW1ycVJ0UENaZEplYTFKdUxWVEJpal8zVm1EbnlnSHBHY3ZjY0dRY094elVKU0tJTWxxM1JCWTN1UkhnUGtMMGxlUEhuUzFYRHg4eUEzN1R1bFhUTnpfaX…
SL Science Holding Limited - Ordinary Shares (Nasdaq:SLBT) Stock Quote - FinancialContent
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE56SVNNaG9mSnhQOXpmQlZ6U090Y09pd1Bld3B0bmhjN0U0WkRucVh4N2R0UndSZUVmSmhpS2YyampoT1ZjT3VNblNVNlJLYURIMWRhY2s4YjdNN2VhUkZWREpoN1ZpbnRuQnpkVXVMLWtZYXFNc3hPSmtuX0Q4UQ?oc=5" target="_blan…
Off-the-shelf cancer cell therapy firm joins Nasdaq in $5.6B SPAC deal - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOQVhKYzJZZC1oUWJxMmZpLWhySy1YQk96U09KdjZOYXZUNG5xWmFYYnJURjlRSHB3bURKaUpWODVyWDRkb3RCejh5VmkzTFYxdVBIRTh3ZEdfbXQ0UnJVRjdfX1BjZVVNZGMyOVEzMVlRd3l4TjljMC1SLVp3UlhzZXlUOW5vZG8zYmJCX0…
SLBT — Frequently Asked Questions
What is the current share price of SLBT?
As of 2026-08-05 17:25 PDT, SLBT trades at $2.80 on NASDAQ/NYSE. Its 52-week range is $2.60 to $12.81.
What is the market capitalisation of SLBT?
SLBT has a market capitalisation of $1.57B on NASDAQ/NYSE.
What is the P/E ratio of SLBT?
SLBT trades at a trailing price-to-earnings (P/E) ratio of -1,318.27. Its price-to-book (P/B) ratio is 682.93.
Is SLBT a good stock to buy?
This page provides a data-driven analysis of SLBT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.